All In Biotech

Drug Trial Radar · NCT00560755

Safety Study of ProQuad® rHA in Infants (V221-037)

An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life

Last checked: Nov 20, 2026Latest source record: Oct 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,388

Actual

Start

Oct 24, 2007

Primary completion

Nov 24, 2008

Study completion Nov 24, 2008

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 20, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 22 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life. Secondary objectives: To describe the safety profile of a first dose of ProQuad® manufactured with rHA when administered to children in their second year of life.

Conditions

  • Measles
  • Mumps
  • Rubella
  • Varicella

Interventions

  • ProQuad®Biological

    ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
  2. Percentage of Participants Experiencing a Vaccine-related AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
  3. Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 2Time frame: Up to Day 46 (for 4 days following ProQuad® Dose 2)
  4. Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
  5. Percentage of Participants Experiencing a Injection-site Rash of Interest AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
  6. Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
  7. Percentage of Participants Experiencing a Vaccine-related Systemic AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
  8. Percentage of Participants Experiencing a Non-injection-site Rash of Interest AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
  9. Percentage of Participants Experiencing a Mumps-like Illness After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
  10. Percentage of Participants Experiencing a Serious AE (SAE) After ProQuad® Dose 2Time frame: Up to Day 84 (up to 42 days after ProQuad® Dose 2)
  11. Percentage of Participants Experiencing a Vaccine-related SAE After ProQuad® Dose 2Time frame: Up to Day 84 (up to 42 days after ProQuad® Dose 2)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.